---
title: "08:35 ETHalia Therapeutics Announces Presentation at the BIO Investment & Growth Summit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277474512.md"
description: "Halia Therapeutics, a clinical-stage biopharmaceutical company, announced its presentation at the BIO Investment & Growth Summit on March 2, 2026. CEO David Bearss will discuss the company's strategy, platform, and clinical programs. Halia focuses on developing first-in-class inflammasome inhibitors to address inflammation-driven diseases by targeting NEK7, a key regulator of inflammasome activation."
datetime: "2026-03-02T13:35:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277474512.md)
  - [en](https://longbridge.com/en/news/277474512.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277474512.md)
---

# 08:35 ETHalia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

, /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver a company presentation at the BIO Investment & Growth Summit.

David Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, will present an overview of the company's strategy, platform, and clinical programs.

**Presentation Details**

**Event:** BIO Investment & Growth Summit  
**Date/Time:** Monday, March 2, 2026 at 2:30 PM  
**Location:** Ballroom I, Salon C

**About NEK7**

NEK7 is a critical regulator of inflammasome activation and a required component for assembly and activation of the NLRP3 inflammasome. Activation of this pathway can drive the release of proinflammatory cytokines, including IL-1β and IL-18, contributing to chronic inflammation across hematology, cardiometabolic, pain, and other inflammation-driven diseases. Targeting NEK7 offers a pathway-level approach to modulating NLRP3 inflammasome activity upstream, providing a differentiated strategy versus blocking individual downstream cytokines.

**About Halia Therapeutics**

Halia Therapeutics is a biotechnology company developing first-in-class inflammasome inhibitors. We target the root causes of inflammation-driven diseases to create transformative therapies.

**Media Contact  
****Taylor Avei  
**Director of Business Development  
Halia Therapeutics  
\[email protected\]

SOURCE Halia Therapeutics

### Related Stocks

- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIS.US](https://longbridge.com/en/quote/BIS.US.md)

## Related News & Research

- [Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference](https://longbridge.com/en/news/282940584.md)
- [08:00 ETLynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA](https://longbridge.com/en/news/282340368.md)
- [Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002](https://longbridge.com/en/news/282660503.md)
- [CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months](https://longbridge.com/en/news/282582813.md)
- [Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)](https://longbridge.com/en/news/283014601.md)